Cargando…
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Severe asthma has a substantial epidemiological impact on children and biological treatments can be an option to take into account, as they target specific molecules and pathways involved in its pathogenesis. Modern medicine is continuously and progressively oriented towards tailored treatments desi...
Autores principales: | Giovannini, Mattia, Mori, Francesca, Barni, Simona, de Martino, Maurizio, Novembre, Elio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883618/ https://www.ncbi.nlm.nih.gov/pubmed/31779657 http://dx.doi.org/10.1186/s13052-019-0737-4 |
Ejemplares similares
-
Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection
por: Paladini, Erika, et al.
Publicado: (2021) -
From the Global Initiative for Asthma report and asthma guidelines to real-life asthma control: is there room for improvement?
por: Novembre, Elio, et al.
Publicado: (2022) -
Venom immunotherapy protocols in the pediatric population: how to choose?
por: Saretta, Francesca, et al.
Publicado: (2023) -
Oral desensitization to milk: how to choose the starting dose!
por: Mori, Francesca, et al.
Publicado: (2010) -
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)